Table 2 Treatment-emergent adverse events, discontinuation, and deaths at 18Â months from randomization (safety population)
|  | KRd (n = 392) | Rd (n = 389) |
|---|---|---|
Patients with any-grade AE, n (%) | 379 (96.7) | 372 (95.6) |
Grade ≥ 3 AE, n (%) | 315 (80.4) | 293 (75.3) |
Serious AEs, n (%) | 211 (53.8) | 180 (46.3) |
AE leading to treatment discontinuation, n (%) | 83 (21.2) | 81 (20.8) |
AE leading to death, n (%) | 25 (6.4) | 29 (7.5) |
Any-grade AEs of interest, n (%) | ||
 Anemia | 157 (40.1) | 147 (37.8) |
 Thrombocytopenia | 107 (27.3) | 84 (21.6) |
 Neutropenia | 137 (34.9) | 126 (32.4) |
 Hypertension | 51 (13.0) | 23 (5.9) |
 Dyspnea (HLT) | 82 (20.9) | 67 (17.2) |
 Peripheral neuropathy (SMQN) | 59 (15.1) | 55 (14.1) |
 Cardiac failure (SMQN) | 23 (5.9) | 13 (3.3) |
 Acute renal failure (SMQN) | 26 (6.6) | 24 (6.2) |
Grade ≥ 3 AEs of interest, n (%) | ||
 Anemia | 69 (17.6) | 65 (16.7) |
 Thrombocytopenia | 63 (16.1) | 47 (12.1) |
 Neutropenia | 111 (28.3) | 99 (25.4) |
 Hypertension | 16 (4.1) | 5 (1.3) |
 Dyspnea | 10 (2.6) | 6 (1.5) |
 Peripheral neuropathy (SMQN) | 9 (2.3) | 9 (2.3) |
 Cardiac failure (SMQN) | 14 (3.6) | 5 (1.3) |
 Acute renal failure (SMQN) | 9 (2.3) | 12 (3.1) |